Immunocompromised Human Serum Albumin/Human Neonatal Fc Receptor Mouse Model
Our double-humanized serum albumin/neonatal Fc receptor mouse model (HSA/hFcRn) maintains an autologous receptor-ligand interaction and can mimic the physiological drug clearance in humans.
This upgraded, immunocompromised Rag1-/- system (HSA/hFcRn/Rag1-/-) allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.
Applications
- Efficacy assessment of drug conjugates, antibodies (e.g., T-cell engagers), and any albumin- and FcRn-binding compounds
- Accurate and predictive PK/PD studies of albumin- and FcRn-binding compounds
|
Request a quote to get pricing, offers and HSA/hFcRn/Rag1-/- model information by phone or email. |
HSA/hFcRn/Rag1-/- model features
- Murine Rag1 is invalidated, leading to a deficiency in T- and B-cell development
- Physiological HSA and hFcRn expression profile and regulation in a mouse system, as they are both controlled by their respective endogenous mouse promoters (murine albumin and FcRn expression is abolished)
- Efficient tumor growth upon human cancer cells injection
HSA/hFcRn/Rag1-/- model validation
|
CD3+ T-cell and CD19+ B-cell development is abolished in HSA/hFcRn/Rag1-/- mice Hemocytometer (A) and flow cytometry count of B and T cells in the thymus (B) and spleen (C) of wild-type (WT) and HSA/hFcRn/Rag1-/- (tHO) mice. |
|
Humanization of serum albumin and FcRn does not affect tumor growth in HSA/hFcRn/Rag1-/- mice
C57BL6 Rag1-/- (C57BL6 Rag1 KO) and HSA/hFcRn/Rag1-/- (AlbuMus RAG1 KO) mice were subcutaneously inoculated with HT-29 cells (colorectal cancer cells). |
|
Compound efficacy assessment in human breast and pancreatic cancer-cell xenografts HSA/hFcRn/Rag1-/- mice were subcutaneously inoculated with MDA-MB-231 (left) or MIA PaCa-2 (right) cells. Mice were randomized and treated either with vehicle or with an albumin-bound drug once a week for 4 weeks, when individual tumor reached 250mm3. |
* For more validation data please contact us.
Reference
Ole A Mandrup, Sui Ching Ong, Simon Lykkemark, Anders Dinesen, Imke Rudnik-Jansen, Niels Frederik Dagnæs-Hansen, Jan Terje Andersen, Luis Alvarez-Vallina, Kenneth A Howard.
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
Commun Biol. 2021 Mar 8
Further reading
- Immunocompromised HSA/hFcRn Mouse Model: A New Xenograft Model for Efficacy Studies of Immunotherapies
- Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?
- HSA/hFcRn, a Powerful Model for Your PK/PD Studies
Ready to be shipped to your lab
- Cohorts available upon request
- Studies can be carried out at your site or at your favorite CRO
- SOPF certification and worldwide delivery by professional breeders
- Models provided with FTO on patent-protected technologies used for model generation